CAR-T State of the Art and Future Challenges, A Regulatory Perspective.

ABSTRACT: This review is an outlook on CAR-T development up to the beginning of 2023, with a special focus on the European landscape and its regulatory field, highlighting the main features and limitations affecting this innovative therapy in cancer treatment. We analysed the current state of the art in the EU and set out a showcase of the field's potential advancements in the coming years. For this analysis, the data used came from the available scientific literature as well as from the European Medicines Agency and from clinical trial databases. The latter were investigated to query the studies on CAR-Ts that are active and/or relevant to the review process. As of this writing, CAR-Ts have started to move past the "ceiling" of third-line treatment with positive results in comparison trials with th

SUBMITTER: Giorgioni L 

PROVIDER: S-EPMC10380644 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature